{"filing":{"accession_number":"0001493152-26-034185","cik":"0001962011","ticker":"KAPA","company_name":"Kairos Pharma, LTD.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/form8-k.htm"},"events":[{"id":19375,"run_id":17434,"accession_number":"0001493152-26-034185","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Kairos Pharma announced entry into a strategic collaboration agreement with Bayer to evaluate ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer. This is a material operational/strategic partnership targeting a $570M–$1.3B addressable market, but it does not constitute a material acquisition, merger, or change of control (ma_activity), nor does it fit other specific event categories. The collaboration represents a significant clinical and commercial milestone for the company's lead candidate.","company_name":"Kairos Pharma, LTD.","ticker":"KAPA","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18449,"accession_number":"0001493152-26-034185","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kairos Pharma announced entry into a strategic collaboration agreement with Bayer to evaluate ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer. This is a material operational/strategic partnership targeting a $570M–$1.3B addressable market, but it does not constitute a material acquisition, merger, or change of control (ma_activity), nor does it fit other specific event categories. The collaboration represents a significant clinical and commercial milestone for the company's lead candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:36:57.429931+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18449,"accession_number":"0001493152-26-034185","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Kairos Pharma announced entry into a strategic collaboration agreement with Bayer to evaluate ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer. This is a material operational/strategic partnership targeting a $570M–$1.3B addressable market, but it does not constitute a material acquisition, merger, or change of control (ma_activity), nor does it fit other specific event categories. The collaboration represents a significant clinical and commercial milestone for the company's lead candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:36:57.429931+00:00","company_name":"Kairos Pharma, LTD.","ticker":"KAPA","filing_date":"2026-07-22"}]}